Somaxon Pharmaceuticals to Present at the 11^th Annual BIO CEO & Investor Conference

SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) today announced that Richard Pascoe, president and chief executive officer, will present a company overview at the 11^th Annual BIO CEO & Investor Conference at the Waldorf-Astoria in New York City on Monday, February 9, 2009, at 12:45 p.m. PT (3:45 p.m. ET).

A live webcast of the presentation will be available in the Investor Relations section of the company’s website under Event Scheduler at www.somaxon.com. The webcast will be archived and accessible for at least 14 days.

About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. A New Drug Application (NDA) for Silenor^® (doxepin), Somaxon’s drug candidate for insomnia, has been filed with the U.S. Food and Drug Administration and currently is under review.

For more information, please visit the company’s web site at www.somaxon.com.